Oct 22, 2023
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Oct 15, 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
Oct 02, 2023
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Sep 20, 2023
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Sep 05, 2023
Immutep to Participate in September Investor Conferences
Aug 01, 2023
Immutep Receives Positive Scientific Advice from European Medicines Agency
Jul 31, 2023
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
Immutep Quarterly Activities Report Q4 FY23
Jul 28, 2023
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Jun 27, 2023
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Immutep Completes A$80 Million Capital Raise
Jun 20, 2023
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Jun 07, 2023
Immutep to Participate at the Jefferies Healthcare Conference
Jun 05, 2023
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Jun 02, 2023
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
